Patents are essential in the pharmaceutical industry to ensure commercial viability and financial returns but how do they effect public access to vaccines in a pandemic?
Outside the pandemic, “investigational” remains payer code for denying reimbursement. In the case of treatment for chronic conditions, even FDA-approved digital-health and connected devices languish on waitlists for formulary inclusion.